Sanofi Form 6-K June 02, 2014

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2014

Commission File Number: 001-31368

## **SANOFI**

(Translation of registrant s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is subn	nitting the Form 6-K in paper	as permitted by Regulation S-T F	Rule 101(b)(1): o
Indicate by check mark if the registrant is subn	nitting the Form 6-K in paper	as permitted by Regulation S-T F	Rule 101(b)(7): o
Indicate by check mark whether the registrant the Commission pursuant to Rule 12g3-2(b) un			creby furnishing the information to
	Yes o	No x	
If Yes marked, indicate below the file numb	per assigned to the registrant in	n connection with Rule 12g3-2(b)	): 82-

In June 2014, Sanofi issued the statements attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

#### **Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated May 28, 2014: Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
Exhibit 99.2	Press release dated May 30, 2014: Genzyme s Lemtrada Resubmission Accepted for Review by FDA
	2

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 2, 2014 **SANOFI** 

By /S/ John Felitti

Name: John Felitti

Title: Associate Vice President,

Corporate Law, Financial &

Securities Law

3

#### **Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated May 28, 2014: Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
Exhibit 99.2	Press release dated May 30, 2014: Genzyme s Lemtrada Resubmission Accepted for Review by FDA
	4